CO6230995A2 - Antagonistas de activina-actrii y usos para aumentar los niveles de globulos rojas - Google Patents

Antagonistas de activina-actrii y usos para aumentar los niveles de globulos rojas

Info

Publication number
CO6230995A2
CO6230995A2 CO09071017A CO09071017A CO6230995A2 CO 6230995 A2 CO6230995 A2 CO 6230995A2 CO 09071017 A CO09071017 A CO 09071017A CO 09071017 A CO09071017 A CO 09071017A CO 6230995 A2 CO6230995 A2 CO 6230995A2
Authority
CO
Colombia
Prior art keywords
polypeptide
seq
acid sequence
amino acid
levels
Prior art date
Application number
CO09071017A
Other languages
English (en)
Inventor
Matthew L Sherman
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CO6230995A2 publication Critical patent/CO6230995A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

1.- Un método para aumentar los niveles de glóbulos rojos en un paciente humano, comprendiendo el método administrar a un paciente humano que lo necesita una cantidad eficaz de un polipéptido ActRIl seleccionado entre el grupo que consiste en: a) un polipéptido que comprende una secuencia de aminoácidos al menos el 90% idéntica a SEC ID N°: 2; b) un polipéptido que comprende una secuencia de aminoácidos al menos el 90% idéntica a SEC ID N°: 3 y c) un polipéptido que comprende al menos 50 aminoácidos consecutivos seleccionados de SEC ID N°: 2.d) un polipéptido que comprende una secuencia de aminoácidos al menos el 90% idéntica a SEC ID N°: 16; e) un polipéptido que comprende una secuencia de aminoácidos al menos el 90% idéntica a SEC ID N°: 17 y f) un polipéptido que comprende al menos 50 aminoácidos consecutivos seleccionados de SEC ID N°: 16. 2.- El método de la reivindicación 1, en el que polipéptido tiene una o más de las siguientes características:i) se une a un ligando de ActRIl con una KD de al menos 10-7 M y ii) inhibe la señalización de ActRll en una célula. 3.- El método de la reivindicación 1, en el que dicho polipéptido es una proteína de fusión que incluye, además de un dominio de polipéptido ActRIl, una o más partes de polipéptido que mejoran una o más de estabilidad in vivo, semivida in vivo, captación/administración, localización o distribución tisular, formación de complejos proteicos y/o purificación.
CO09071017A 2006-12-18 2009-07-09 Antagonistas de activina-actrii y usos para aumentar los niveles de globulos rojas CO6230995A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87568206P 2006-12-18 2006-12-18

Publications (1)

Publication Number Publication Date
CO6230995A2 true CO6230995A2 (es) 2010-12-20

Family

ID=39183159

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09071017A CO6230995A2 (es) 2006-12-18 2009-07-09 Antagonistas de activina-actrii y usos para aumentar los niveles de globulos rojas

Country Status (29)

Country Link
US (7) US7988973B2 (es)
EP (6) EP2468291B1 (es)
JP (8) JP5415279B2 (es)
KR (6) KR101688228B1 (es)
CN (4) CN105582521A (es)
AU (1) AU2007334333B2 (es)
BR (1) BRPI0720476B1 (es)
CA (1) CA2672758C (es)
CO (1) CO6230995A2 (es)
CR (1) CR10889A (es)
DK (2) DK2124999T3 (es)
EA (3) EA035911B1 (es)
EC (1) ECSP099514A (es)
ES (1) ES2396734T3 (es)
HK (3) HK1137368A1 (es)
HR (1) HRP20121035T1 (es)
IL (5) IL199451A (es)
ME (1) ME02335B (es)
MX (1) MX2009006651A (es)
MY (3) MY170509A (es)
NZ (4) NZ720955A (es)
PL (2) PL2124999T3 (es)
PT (1) PT2124999E (es)
RS (1) RS52537B (es)
SG (1) SG10201702157QA (es)
SI (1) SI2124999T1 (es)
UA (2) UA101309C2 (es)
WO (1) WO2008076437A2 (es)
ZA (2) ZA200904454B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989276B2 (en) 2001-05-10 2006-01-24 Battelle Energy Alliance, Llc Rapid classification of biological components
USRE46351E1 (en) 2001-05-10 2017-03-28 Battelle Energy Alliance, Llc Antibody profiling sensitivity through increased reporter antibody layering
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
IN2015DN02553A (es) 2005-11-23 2015-09-11 Acceleron Pharma Inc
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
PT2124999E (pt) 2006-12-18 2013-01-22 Acceleron Pharma Inc Antagonistas de activina-actrii e usos para tratar anemia
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008094708A2 (en) * 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US20080286881A1 (en) * 2007-05-14 2008-11-20 Apel William A Compositions and methods for combining report antibodies
CN101861161B (zh) * 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
DK2318028T3 (da) * 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
CA2729100C (en) * 2008-06-26 2018-01-02 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
AU2015202035B2 (en) * 2008-08-14 2017-03-23 Acceleron Pharma Inc. Use of GDF traps to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) * 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
WO2010062383A2 (en) 2008-11-26 2010-06-03 Amgen Inc. Stabilized receptor polypeptides and uses thereof
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc METHODS FOR INCREASING ADIPONECTIN
MX355042B (es) * 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
WO2010151426A1 (en) * 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
CN113082194A (zh) * 2009-08-13 2021-07-09 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
AU2010292203A1 (en) * 2009-09-09 2012-04-12 Acceleron Pharma Inc. ActRIIb antagonists and dosing and uses thereof
US9410965B2 (en) * 2009-09-17 2016-08-09 Battelle Energy Alliance, Llc Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
US8969009B2 (en) * 2009-09-17 2015-03-03 Vicki S. Thompson Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (es) * 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2014030683A1 (ja) * 2012-08-21 2014-02-27 国立大学法人九州大学 貧血患者の貧血の要因を検出するためのバイオマーカー
EP3527219A1 (en) * 2012-10-24 2019-08-21 Celgene Corporation Methods for treating anemia
EP3608419A1 (en) * 2012-10-24 2020-02-12 Celgene Corporation Biomarker for use in treating anemia
KR20220156979A (ko) * 2012-11-02 2022-11-28 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
CN106795224B (zh) 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
BR112017011722A2 (pt) * 2014-12-03 2018-02-27 Acceleron Pharma Inc antagonistas de activina-actrii e usos para o tratamento de anemia
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016123454A1 (en) * 2015-01-29 2016-08-04 Board Of Trustees Of Miching State University Cryptic polypeptides and uses thereof
EP3256148A1 (en) 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
KR20170129233A (ko) 2015-03-26 2017-11-24 악셀레론 파마 인코포레이티드 폴리스타틴-관련된 융합 단백질 및 이들의 용도
AU2016244750B2 (en) 2015-04-06 2021-02-18 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
KR20180006386A (ko) 2015-04-22 2018-01-17 얼라이브젠 유에스에이 인코포레이티드 신규한 근육 소모 질환 치료용 하이브리드 ａｃｔｒｉｉｂ 리간드 트랩 단백질
CA2985777A1 (en) * 2015-05-13 2016-11-17 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
CA2986432A1 (en) 2015-05-20 2016-11-24 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
EP3321319B1 (en) * 2015-07-06 2022-10-05 Mitsubishi Gas Chemical Company, Inc. Resin composition and prepreg, resin sheet, laminate plate, and printed circuit board
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
WO2017177013A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3496739B1 (en) 2016-07-15 2021-04-28 Acceleron Pharma Inc. Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
JP6944768B2 (ja) 2016-08-29 2021-10-06 エア・ウォーター株式会社 ペリクルの製造方法
KR20230152811A (ko) 2016-10-05 2023-11-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
EP3538128A4 (en) 2016-11-10 2020-07-22 Keros Therapeutics, Inc. ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
CA3054837A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
CN111801112A (zh) 2017-11-09 2020-10-20 科乐斯疗法公司 激活素受体iia型变体及其使用方法
CN112292144A (zh) 2018-01-12 2021-01-29 科乐斯疗法公司 激活素受体iib型变体及其使用方法
KR20210006952A (ko) * 2018-05-09 2021-01-19 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
EP4065607A1 (en) 2019-11-29 2022-10-05 Kymab Limited Treatment for physiological iron overload
CA3226249A1 (en) * 2021-08-16 2023-02-23 Thermolife International, Llc Iron supplement compositions and methods of use thereof
US11945856B2 (en) 2022-01-28 2024-04-02 35Pharma Inc. Activin receptor type IIB variants and uses thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US71927A (en) * 1867-12-10 Improvement in apparatus fob turning on gas
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
AU8761391A (en) * 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
AU654724B2 (en) 1991-05-10 1994-11-17 Salk Institute For Biological Studies, The Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
EP0726948B1 (en) 1993-10-14 2007-02-28 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
EP0771873A3 (en) 1995-10-27 1998-03-04 Takeda Chemical Industries, Ltd. Neuronal cell-specific receptor protein
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
CN100567322C (zh) 1999-01-21 2009-12-09 梅塔莫菲克斯公司 抑制生长分化因子活性的多肽及表达该多肽的细胞
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
DE60026592T2 (de) * 1999-12-15 2006-12-14 Research Development Foundation, Carson City Betaglycan als ein inhibin rezeptor und dessen verwendung
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
PL375045A1 (en) 2002-02-21 2005-11-14 Wyeth Gasp1: a follistatin domain containing protein
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
JP2004121008A (ja) * 2002-09-30 2004-04-22 Toray Ind Inc ネコアクチビンａおよびそのサブユニット並びにその製造法
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004086953A2 (en) 2003-03-26 2004-10-14 The Board Of Trustees Of The University Of Arkansas Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
AU2004245025A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005009460A2 (en) * 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
EP1732589A2 (en) 2004-03-26 2006-12-20 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
AU2005230854A1 (en) 2004-03-31 2005-10-20 Xencor, Inc BMP-7 variants with improved properties
WO2006002387A2 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. Gdf3 propeptides and related methods
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
EP1804824B1 (en) 2004-09-29 2017-01-04 Icahn School of Medicine at Mount Sinai Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
AU2005307789A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
ES2547866T3 (es) 2005-02-16 2015-10-09 The General Hospital Corporation Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
JPWO2006115274A1 (ja) * 2005-04-26 2008-12-18 味の素株式会社 骨髄赤血球前駆細胞分化促進剤
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
IN2015DN02553A (es) * 2005-11-23 2015-09-11 Acceleron Pharma Inc
AU2006321906C1 (en) 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
EP1976541B1 (en) 2006-01-20 2011-07-13 Beckman Coulter, Inc. Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency
WO2007133653A2 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
US8591938B2 (en) 2006-07-21 2013-11-26 Lyne Laboratories, Inc. Liquid compositions of calcium acetate
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
PT2124999E (pt) 2006-12-18 2013-01-22 Acceleron Pharma Inc Antagonistas de activina-actrii e usos para tratar anemia
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
WO2008151078A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
ES2617957T3 (es) 2007-08-03 2017-06-20 Summit (Oxford) Limited Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
WO2009137613A2 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis

Also Published As

Publication number Publication date
EA202091230A2 (ru) 2020-09-30
EP2124999B1 (en) 2012-10-03
KR20090096517A (ko) 2009-09-10
BRPI0720476B1 (pt) 2022-05-31
US20210355191A1 (en) 2021-11-18
US20090047281A1 (en) 2009-02-19
ME02335B (me) 2013-04-30
JP2021080290A (ja) 2021-05-27
EP3320911A2 (en) 2018-05-16
EP2468290B1 (en) 2015-04-01
KR20180019768A (ko) 2018-02-26
IL240524A (en) 2017-06-29
JP2016020391A (ja) 2016-02-04
CN104524548A (zh) 2015-04-22
EP3320911A3 (en) 2018-06-27
ES2396734T3 (es) 2013-02-25
EA035911B1 (ru) 2020-08-31
EP4026553A1 (en) 2022-07-13
KR20150064239A (ko) 2015-06-10
CR10889A (es) 2009-09-01
US20090163417A1 (en) 2009-06-25
KR102223231B1 (ko) 2021-03-08
JP5865281B2 (ja) 2016-02-17
WO2008076437A9 (en) 2008-11-13
JP2019089850A (ja) 2019-06-13
ZA200904454B (en) 2014-03-26
NZ720955A (en) 2019-07-26
US8007809B2 (en) 2011-08-30
BRPI0720476A2 (pt) 2014-01-14
IL240524A0 (en) 2015-10-29
KR20160013269A (ko) 2016-02-03
EA201201199A1 (ru) 2013-10-30
RS52537B (en) 2013-04-30
WO2008076437A3 (en) 2008-09-18
IL240523A (en) 2017-12-31
JP2013127002A (ja) 2013-06-27
CN101687015B (zh) 2016-08-03
MY188973A (en) 2022-01-17
SG10201702157QA (en) 2017-04-27
CN101687015A (zh) 2010-03-31
HRP20121035T1 (hr) 2013-01-31
UA101309C2 (ru) 2013-03-25
KR101688228B1 (ko) 2016-12-21
US20200031903A1 (en) 2020-01-30
CN105797135A (zh) 2016-07-27
EP2124999A2 (en) 2009-12-02
IL199451A (en) 2015-08-31
JP2014040483A (ja) 2014-03-06
SI2124999T1 (sl) 2013-02-28
JP5415279B2 (ja) 2014-02-12
EP2468291B1 (en) 2017-11-22
KR101831534B1 (ko) 2018-02-22
MY162136A (en) 2017-05-31
UA116871C2 (uk) 2018-05-25
EP3320911B1 (en) 2021-12-01
EA200970603A1 (ru) 2009-12-30
DK2468290T3 (en) 2015-06-01
JP2017155064A (ja) 2017-09-07
EA202091230A3 (ru) 2021-01-29
MY170509A (en) 2019-08-08
PL2124999T3 (pl) 2013-03-29
CA2672758A1 (en) 2008-06-26
AU2007334333A1 (en) 2008-06-26
US20120052067A1 (en) 2012-03-01
ECSP099514A (es) 2009-08-28
AU2007334333B2 (en) 2013-05-30
WO2008076437A2 (en) 2008-06-26
KR101803620B1 (ko) 2017-11-30
KR20200030124A (ko) 2020-03-19
US20220204588A1 (en) 2022-06-30
MX2009006651A (es) 2009-08-26
EP2446896A1 (en) 2012-05-02
US20100204092A1 (en) 2010-08-12
HK1209624A1 (en) 2016-04-08
EP2468291A1 (en) 2012-06-27
NZ707292A (en) 2017-06-30
PL2468290T3 (pl) 2015-08-31
NZ577847A (en) 2012-06-29
IL256247B (en) 2021-07-29
CA2672758C (en) 2019-07-30
EA018037B1 (ru) 2013-05-30
HK1254840A1 (zh) 2019-07-26
IL284693A (en) 2021-08-31
EP2468290A1 (en) 2012-06-27
JP2017075187A (ja) 2017-04-20
DK2124999T3 (da) 2013-01-14
KR20210027508A (ko) 2021-03-10
NZ617196A (en) 2015-06-26
PT2124999E (pt) 2013-01-22
IL256247A (en) 2018-02-28
HK1137368A1 (en) 2010-07-30
JP2010513506A (ja) 2010-04-30
IL240523A0 (en) 2015-10-29
ZA201202027B (en) 2013-02-27
AU2007334333A2 (en) 2011-05-12
US7988973B2 (en) 2011-08-02
CN105582521A (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
CO6230995A2 (es) Antagonistas de activina-actrii y usos para aumentar los niveles de globulos rojas
AR065289A1 (es) Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple
ES2699658T3 (es) Composiciones para su uso en el tratamiento de lesión neural inhibiendo la actividad de fosfatasas de la familia LAR
JP2018522563A5 (es)
ES2389697T3 (es) Variantes de desintegrina y usos farmacéuticos de los mismos
ES2956510T3 (es) Péptido penetrante celular, conjugado que lo comprende y composición que comprende el conjugado
ES2661500T3 (es) Variantes de HMGB1 y sus usos
ES2750008T3 (es) Células madre mesenquimatosas modificadas genéticamente que expresan klotho
RU2705786C2 (ru) Gla домены в качестве терапевтических агентов
Burgess et al. Matrikines and the lungs
ES2541780T3 (es) Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
JP2012523438A5 (es)
AR035786A2 (es) Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
RU2009132663A (ru) АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
ES2899895T3 (es) Procedimientos de tratamiento de calcificación tisular
PE20130589A1 (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
BRPI0109494B8 (pt) muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
ES2372388T3 (es) Complejos de factores de crecimiento y modulación de migración y crecimiento celular.
ES2308200T3 (es) Peptido derivado de rasgap para destruir selectivamente celulas cancerosas.
CA2131389A1 (en) Thrombin receptor antagonists
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
ES2743767T3 (es) Agente para prevenir y/o tratar dolor neuropático periférico causado por un fármaco anticancerígeno
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
Hur et al. Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide

Legal Events

Date Code Title Description
FC Application refused